e-Drug3D

2060

DEUCRAVACITINIB

INN
DEUCRAVACITINIB

cas 1609392-27-9

CLASS

IMMUNOSUPPRESSANTS
IMMUNOMODULATING AGENTS
TYROSINE KINASE 2 (TYK2) ALLOSTERIC INHIBITOR
TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS

ROUTE (list)

ORAL

ATC code

L04AF07

PK parameters

F 99 PERCENT
Tmax 2.5 HOUR
VD 140 LITER
Cl 2.4 LITER / HOUR
PPB 86 PERCENT
t1/2 10 HOUR

Solubility

PH DEPENDENT DECREASES WITH INCREASING PH

Target

TARGET TYROSINE KINASE 2 (TYK2)

PDB
6NZP (CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH COMPOUND-11)

Download experimental 3D coordinates of LB7 with added hydrogens

tyrosine kinase 2 (TYK2) UNIPROT P29597

Download SDF file

3-Pyridazinecarboxamide, 6-[(cyclopropylcarbonyl)amino]-4-[[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino]-N-(methyl-d3)- (ACI)

Formula:
C20H19D3N8O3

Calculated chemical properties:

MW 422.46
NB_atoms 31
XLogP 1.73
PSA 120.04
NB_HD 3
NB_HA 11
fsp3 0.30
Lipinski(0=no;1=yes) 0

FDA
NDA 214958 (label) INN (DEUCRAVACITINIB) SOTYKTU (BRISTOL) APPROVAL= AP YEAR= 2022 NEWMOLECULARENTITY